Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma

Table 1 M6P/IGF2R LOH analysis of paraffin-embedded tissue

Position	Nucleotide	Genotype	Amplicon size (bp)	F1 primer (5’-3’)	R1 primer (5’-3’)	Nested primer (5’-3’)
Exon 6	901	C/G	91	CACCAGGCGTTTGATGTTGG	CTCCAGCAAGGACCTGACTTTC	CCTCCGATGCTGTTGGCGT
Exon 9	1197	A/G	123	ACTAAGTAAGACTGTAATCTTCTAATACC	GTCTGTGGAGAAACTG AAATACAG	AATACCTATTCATATAAAACAAGCCTC
Exon 12	1737	G/A	111	TATTTGTCACAGAGTGCTGCAGG	GGCATCCAGTTTGGAATGAGTTAG	GGAAGATCTAGGTGATGCTTTTC
Exon 16	2286	A/G	187	GAAGCTTTCATATTATGATGGGATG	GAGGATACTCATGCCTGTGGTG	CATCGCGCTCCCTGAGGATACT
Exon 40	6206	A/G	118	GGGTGTGATGTGACATTTGAGTGG	GCCTTCCCAGTCCACCCGC	GGAGTGCAAATTCGTCCAGAAAC
Exon 47	X47-5	t/a	161	ATGCCCTCTCTACACTGGAGTA	GTAAGCTGACCACTTGCTGTAGG	CAGTGATAAGTAAGCTGACC

Table 2 Patient characteristics n (%)

Characteristics	Total patients (n = 30)	Informative patients (n = 22)
Age: yr	36-78 (Median: 58)	39-78 (Median: 59)
Gender: male/female	22 (73.3)/8 (26.7)	16 (72.7)/6 (27.3)
Disease etiology
HBV	18 (60.0)	15 (68.2)
HCV	6 (20.0)	3 (13.6)
Alcohol	6 (20.0)	4 (18.2)
Tumor Grade
Well differentiation	9 (30.0)	6 (27.3)
Moderate differentiation	11 (36.7)	8 (36.4)
Poor differentiation	10 (33.3)	8 (36.4)
Liver Histology
Chronic hepatitis	3 (10.0)	2 (9.1)
Cirrhosis	21 (70.0)	16 (72.7)
Nonspecific reaction	6 (20.0)	4 (18.2)
Tumor size (cm)
< 2	4 (13.3)	2 (9.1)
2-5	14 (46.7)	11 (50.0)
> 5	12 (40.0)	9 (40.9)
No. of Tumor
Single	18 (60.0)	12 (54.5)
Multiple	12 (40.0)	10 (45.5)
AJCC Stage
II	18 (60.0)	12 (54.5)
IIIA	12 (40.0)	10 (45.5)